Skip to main content
Premium Trial:

Request an Annual Quote

Mapper OpGen Snags Variagenics Dykes

Premium

For the last decade, Colin Dykes has been setting up and running genomics shops. He began by devising Glaxo’s genomics program in 1993, and in 1998 joined Variagenics, where he guided the company over the last four years as vice president of research. Now, the Northern Ireland native has relocated to Madison, Wis., where he assumes the role of CSO at optical mapping company OpGen.

Dykes met David Schwartz, an academic founder of OpGen, while he was at Variagenics. “So when I was contacted about this opportunity” — after he left Variagenics as a result of a change in strategic focus — “I knew a lot about optical mapping,” he says. The technology relies on immobilizing single molecules of DNA on a substrate to visualize them.

According to Dykes, 49, the company has already sold several maps to academic and commercial labs, primarily for microbial and plant genome sequencing. The technology is particularly conducive to finding blocks of SNPs, an area with which Dykes is quite familiar. “It’s become apparent that haplotypes are much more powerful than looking at SNPs,” he says. “OpGen is looking for longer-scale haplotypes across large areas of the chromosome.”

Other applications of the technology lie in some of today’s hot spots. “This method also has the potential to be used for high-throughput sequencing,” Dykes says, adding that it’s one of only a couple of technologies that can look at single DNA molecules to study an entire genome. Also, the optical mapping concept might be applied to typing pathogens.

Oncology studies are another angle Dykes is pursuing for the company. In theory, a doctor could send a tumor sample to OpGen, which would identify the DNA rearrangements that have occurred to determine the progress of the tumor as well as to recommend a course of therapy. The work to establish correlations between tumor state and drug response is something OpGen will delve into next year, Dykes says.

— Meredith Salisbury

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.